Melanoma is a most aggressive skin cancer with limited therapeutic options and its incidence is increasing rapidly in recent years. The discovery and application of new targeted therapy agents have shown significant benefits. However, adverse sideeffects and resistance to chemotherapy remain formidable challenges in the clinical treatment of malignant melanoma. Nanotherapeutics offers an important prospect of overcoming these drawbacks. The anti-tumoral applications of nanomedicine are varied, including those in chemotherapy, RNA interference, photothermal therapy, and photodynamic therapy. Furthermore, nanomedicine allows delivery of the effector structures into the tumor site via passive or active targeting, thereby allowing increased therapeutic specificity and reduced side effects. In this review, we summarize the latest developments in the application of nanocarrier-mediated targeted drug delivery to melanoma and nanomedicine-related clinical trials in melanoma treatment. We also discuss existing problems and opportunities for future developments, providing direction and new thoughts for further studies.
Malignant melanoma is a malignant tumor originating from melanocytes. It accounts for only 4% of skin cancers, but results in 79% of skin cancer-related deaths. 1 The incidence of melanoma has continued to increase in recent decades, and melanoma tends to affect younger people. 2 The most common clinical treatment for melanoma is surgery combined with radiation and chemotherapy. Surgery is a primary mode of treatment for localized cutaneous melanoma, and metastasectomy is the surgical excision employed for patients with solitary melanoma metastasis. 3 Chemotherapeutic drugs for malignant melanoma include dacarbazine (DTIC), temozolomide (TMZ), paclitaxel, and platinum compounds. However, the overall response rate to a single agent is <20%, and these agents have many side effects. 4, 5 Unfortunately, resistance to chemotherapy is a challenge in the treatment of malignant melanoma. Recent developments in immunotherapy and molecularly targeted therapy have improved patients' prospects. Targeting CTLA-4 or PD-1/ PD-L1 does offer an efficient therapeutic modality for melanoma and potential efficacy in other cancers. Unfortunately, these therapies are not effective for all patients. 6 Still, drug resistance and immune-related side effects negatively influence the outcomes of further treatment. 7 Therefore, better targeting of treatment and overcoming the resistance to chemotherapy are vital to improve the overall efficacy of melanoma treatment. 8, 9 Recently, rapid advances in nanotechnology for cancer treatment have been encouraging. 10, 11 Nanodrugs can kill tumor cells directly or can act as carriers for chemotherapy and gene therapy. Photothermal therapy (PTT) and photodynamic therapy (PDT), based on nanomaterials, have received significant attention in cancer treatment. 12 In addition, nanodrugs can target tumor cells passively or actively to improve treatment specificity, while reducing side effects. 13 Several nanodrugs have been approved by the United States Food and Drug Administration (FDA) for clinical treatment, 14 and other nanodrugs currently in pre-clinical or clinical trials have shown potential for tumor treatment. 15 This review summarizes the research progress in nanodrugs for treatment of malignant melanoma. We also discuss existing problems and opportunities for future developments.
and good electrical and optical performance. 17, 18 In medicine, researchers found recently that cerium oxide nanoparticles can induce the formation of reactive oxygen species (ROS), increase the amount of malondialdehyde, generate glutathione, decrease chromosomal condensation, activate caspase 3, and induce double-stranded DNA break in human cutaneous melanoma A375 cells in vitro. 19 The in vivo effects of cerium oxide nanoparticles have yet to be described. Cerium oxide nanoparticles can be used for other cancers, such as lung cancer, 20 pancreatic cancer 21 and liver cancer, 22 ultimately resulting in tumor cell death. However, long-term or highdose exposure of non-cancerous cells to cerium oxide may lead to pulmonary fibrosis. 23 Zinc oxide nanoparticles have also been studied extensively. Alarifi et al. reported that a 17-nm zinc oxide nanoparticle can kill melanoma cells directly through oxidative stress, DNA damage, and induction of apoptosis. 16 In the same way, zinc oxide nanoparticles can kill breast cancer cells and liver cells directly. [24] [25] [26] Extracted from the rhizome of Curcuma longa as a phenolic pigment, curcumin has shown many attractive biomedical functions, including antiinflammatory, anti-oxidant, and anti-cancer effects. 27 It can induce tumor cell cycle blockage and apoptotic cell death by downregulating oncogene expression and upregulating antioncogene expression, interfering with p53-related pathways and blocking nuclear factor (NF)-jB activation. 28, 29 Arunraj et al. synthesized curcumin nanospheres that showed good skin permeation and retention and could reduce melanoma growth by inhibiting glutathione S-transferase activity and COX-1/COX-2 enzymes, inducing apoptosis through the Fas receptor/caspase-8 pathway and down-regulating NF-jB signaling both in vitro and in vivo. 30 These findings provided new insights for tumor treatment. For example, chemotherapeutic drugs can be formulated into nanoparticles to make use of the benefits of both chemotherapy and nanoparticles. 31 The nanoparticles that can be used to directly kill tumor cells are summarized in Table 1 . Notably, there are potential safety hazards associated with some nanomaterials, such as liver and kidney toxicity, neurotoxicity and cardiovascular toxicity, which limit their clinical application. 42, 43 Nanoparticles as Carriers Nanoparticles hold great promise as carriers for anti-tumor treatment. Chemotherapeutic drugs or nucleotide fragments can be adsorbed onto the surface of or encapsulated within nanoparticles through electrostatic force, hydrophilic-hydrophobic properties, or chemical bonds. 44 Therefore, nanocarriers can protect drugs or genes from degradation to improve their stability and bioavailability. 45, 46 Through delivery by nanocarriers, therapeutic agents can permeate efficiently and specifically into tumor tissue via passive or active targeting, thus reducing the side effects in normal tissue. 47 
Nanoparticles as drug carriers
Numerous nanomaterials can be used as drug carriers for tumor treatment, such as liposomes, polymer micelles, silicon dioxide, carbon nanotubes, dendritic polymers, gold, silver and other metal or metal oxides. 48, 49 As drug carriers, nanoparticles must have low toxicity towards normal cells in order to allow repeated treatment. Some of these also have been 
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used to treat melanoma. For example, the anti-melanoma drug doxorubicin, delivered via a nanoliposomal system, displays a good anti-tumor effect. 50 Artemisone, a 10-amino-artemisinin derivative, was enclosed in nano-vesicular niosomes by Dwivedi and colleagues, who found that the delivery system could permeate skin and displayed selective cytotoxicity by inhibiting A375 cells via ROS generation. 51 Muley and others developed a polyethylene glycol (PEG)-modified polymer micelle loaded with paclitaxel, which showed sustained release of paclitaxel and anti-cancer efficacy. 52 Some secondary plant metabolites can also be encapsulated in nanoparticles. Gismondi et al. coupled reduced nanodiamonds (NDs) with ciproten and quercetin and found an enhanced antiproliferative effect in B16F10 tumor-bearing mice. 53 They also reported that ciproten loaded in NDs can inhibit the growth of melanoma cells via an antimitotic effect. 54 The growth and metastasis of a tumor is governed by angiogenesis, which provides oxygen, nutrients, and a route of metastasis for tumor cells. 55 Therefore, blocking angiogenesis is an effective tumor treatment strategy. 56 Wang et al.
synthesized triptolide polymer micelle (TP-PM) nanoparticles and studied their efficacy in tumor-bearing mice. The results showed that after exposure to TP-PMs, plasma vascular endothelial growth factor (VEGF) levels in the mice were significantly decreased; the tumor blood vessel diameter and density were distinctly reduced; tumor growth was reduced by as much as 50%; and the survival of the mice was prolonged. 57 Delivery of chemotherapeutic drugs using nanocarriers can increase the local drug concentration via sustained release or controlled release, 58 leading to efficient killing of tumor cells. 46 Another method for increasing the curative effect of chemotherapy is combined chemotherapy. Guo et al. improved the nanodrug loading methods and successfully built a dual drug (cisplatin and rapamycin)-loaded nanosystem that showed an antiangiogenesis effect, normalized tumor blood vessels, and enhanced drug accumulation in tumor to suppress tumor growth. 59 According to the structural characteristics of tumor tissue, nanoparticles can be localized preferentially to tumor tissue via an enhanced permeability and retention (EPR) effect or via active targeting. 60 The EPR effect is caused by the special pathophysiological characteristics of solid tumors, which include high vascular density, poor structural integrity, lymphatic circumfluence dysfunction, and high concentrations of vascular permeability medium. Improving the EPR effect could increase the drug concentration at the tumor site, thus increasing the antitumor effect. 61 While the EPR effect is only one type of passive targeting, to achieve further specificity, some specific target molecules could be modified on the surface of the nanocarriers 47 ( Fig. 1) . Target agents can identify and combine specifically with molecules that are only expressed, or are overexpressed, in tumor cells compared with non-tumor tissue, thereby reducing the side effects of chemotherapy.
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For example, the epidermal growth factor receptor (EGFR) is overexpressed or abnormally expressed in many solid tumors (e.g., non-small cell lung cancer, prostate cancer, breast cancer and melanoma). [63] [64] [65] [66] [67] Song et al. designed GE11-modified liposomes that can combine specifically and effectively with non-small cell lung cancer cells overexpressing EGFR. 68 The A375 human melanoma cells express large amounts of integrin avb3; therefore, targeting this molecule could increase the intake of nanomedicines. 69 Lee et al.synthesized liposomes modified with tetraiodothyroacetic acid that could target A375 cells and achieve an uptake rate of up to 98.5 6 0.5% per cell, whereas cells with low integrin avb3 expression showed negligible uptake. 70 Zhao's group developed nanoparticles that target the cell-penetrating peptide RGD to deliver curcumin for malignant melanoma treatment. Their results showed that compared with non-targeted drugs, in tumor-bearing mice, the targeted nanodrugs inhibited the growth of tumors significantly. 71 Molecules that could be used in targeted therapy for melanoma are summarized in Table 2 . In general, however, the tumor markers commonly used for targeted therapy are also expressed in nontumorous cells, which will inevitably lead to some adverse effects. Therefore, the need to identify new biomarkers with higher targeting specificity is urgent and significant. Some measures should be taken into consideration in this process. For example, better tumor markers can be screened by proteomics or genomics. In addition, the synergistic effect of a dual-or even multitargeted approach can be used to increase the targeting effect while reducing side effects. There are some ongoing clinical trials of nanoparticlebased approaches for melanoma treatment; for example, a combination of a paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab is being tested relative to ipilimumab as the first-line therapy in a phase II study for treating patients with stage IV melanoma that cannot be removed surgically (clinical trials NCT02158520).
Nanoparticles as gene carriers and protectors
RNA interference (RNAi) is another treatment strategy that has attracted increasing attention in recent years. RNAi is a technology involving specific gene silencing mediated by double-stranded RNA (dsRNA). The dsRNA generates a small interfering RNA (siRNA) complex that blocks gene expression at the level of transcription and the posttranscriptional level. 81 However, siRNAs are not stable and are vulnerable to degradation by nucleases. 82 Gao et al. found that naked siRNA could be degraded within 1 minute after injection into mice. 83 Therefore, the development of safe and stable nanocarriers is particularly necessary. STAT3 is overexpressed in many tumor cells, and inhibition of STAT3 expression could suppress the growth and survival of tumors by inducing apoptosis. 84 Alshamsan et al. built a polyethylenimine (PEI) nanoparticle modified with stearic acid (StA) to load a STAT3-short interfering RNA (siRNA). Their results showed that the nanoparticles could be transferred efficiently into the target cells' cytoplasm after transfection of B16 melanoma cells. The levels of VEGF and STAT3 were reduced significantly, and tumor growth was inhibited. 85 Ragelle et al.
used a chitosan nanoparticle as a carrier to load siRNA for treating melanoma and found that this system showed low cell toxicity, good stability, and high efficiency of gene silencing. 86 Han et al. synthesized positively charged, bovine serum albumin (BSA) nanoparticles to load siRNAs. The positive charge contributed to the higher encapsulation efficiency and increased cellular uptake, resulting in an improved efficiency of siRNA transfection and an excellent cancer therapy effect in the B16 lung metastasis model. 87 Other siRNAs used for melanoma treatment are described in Table 3 .
Optical Treatment for Melanoma
In recent years, optical treatment of tumors has become a research hotspot. Compared with chemotherapy and radiation, it has many advantages, including fewer side effects, the ability to be reused many times without induction of resistance, and the ability to enhance the effects of radiotherapy and chemotherapy. Optical treatment is often referred to as "green therapy" by the international medical field. [96] [97] [98] Light penetration capacity is the key factor for optical treatment; therefore, the development of new optical instruments is urgently required. Optical treatment is a new treatment method that is applied closely in combination with nanotechnology, and it mainly is divided into PTT and PDT.
Photothermal therapy
PTT generally uses near-infrared light with strong penetration as the light source to irradiate nanomaterials taken up by tumor cells. The light energy is transformed into heat, which results in protein denaturation and cell necrosis. 99 A variety of inorganic and organic nanomaterials have been applied in the study of PTT because of their good light-heat conversion abilities. Gold nanomaterials have become a research focus in recent years because of their many advantages, such as ease of synthesis, characterization, and modification; excellent lightheat conversion capability; and good biocompatibility. In animal experiments, Heidari et al. exposed gold-ferrite nanoparticles to an 808 nm near-infrared laser. Compared with the control group, the melanoma tumor volume was reduced significantly. 102 Carbon nanotubes are another attractive light reagent. 103, 104 In recent years, they have been developed rapidly as a PTT reagent for tumor treatment, [105] [106] [107] [108] but the biosafety and stability of carbon nanotubes continue to restrict their application. Therefore, it is important to develop new photothermal reagents. Organic photothermal nanomaterials stand out because of their good biocompatibility, biodegradation, and near infrared absorption. Studies have reported that ICG, IR820, polypyrrole, and other organic materials have good absorption in the near infrared region and can be used for tumor PTT, with several reports suggesting their suitability for PTT. [109] [110] [111] [112] [113] While most of these studies were related to breast and liver cancer, reports of PTT using organic materials in skin cancer are limited. In addition to the thermal ablation effect, recent studies found that PTT can inhibit tumor metastasis 114, 115 and could overcome the multidrug resistance (MDR) of tumors. 116, 117 Whether these effects are applicable to the treatment of melanoma remains to be determined.
Photodynamics therapy
PDT also employs near-infrared light as the light source. Singlet oxygen or active oxygen free radicals generated after photosensitization of tumor cells exposed to near-infrared light induce cell apoptosis and necrosis. 118 Yuan et al. constructed apoly(amidoamine) (PAMAM) copolymer that was covalently bound to the photosensitizer chlorins e6 for melanoma PDT. To improve the curative effect, they modified the RGD target molecules on the nanoparticles. As expected, this method improved the uptake of nanoparticles by cells and enhanced the tumor treatment effect. 119 Silicon phthalocyanine 4 (Pc4) is another type of photosensitizer that has been applied in clinical PDT 120, 121 ; however, its poor dispersion in a liquid environment reduces the effect of PDT, resulting in its limited clinical application. To solve this problem, Zhao et al. developed a method in which silica nanoparticles serve as carriers to load Pc4, which improves its stability and solubility and greatly enhances the effectiveness of PDT for melanoma. 122 Indocyanine green (ICG) is a small organic molecule that has been approved by the FDA for use in clinical near-infrared imaging. 123 ICG is also an ideal photosensitizer. 124 However, its poor stability and non-specific binding to proteins have hampered its application in PDT. Related research that is expected to solve this problem is underway. Mundra et al. encapsulated ICG into a self-assembled nanomicelle to improve its stability and prolong the cycle time inside the organism, thereby increasing the drug concentration at the tumor site. They reported that their nanomicelle system can inhibit the growth of melanoma cells effectively in the near infrared irradiation area, which suggested that encapsulated ICG is a very promising PDT agent. 109 To further improve its curative effect, we could combine PTT and PDT. Surprisingly, some materials can be used not only as photothermal agents but also as photosensitizers. 113, 125, 126 Vankayala et al. found that a gold nanoshell could produce heat for PTT and produce singlet oxygen for PDT under near-infrared light irradiation, which effectively inhibited the growth of melanoma cells. 127 However, inorganic nanomaterials, such as gold particles, are resistant to degradation in vivo, raising controversy over their long-term safety. Therefore, further research is needed before their widespread application. Xia et al. compared the biosafety and biocompatibility of HEPES-prepared GNPs and citric-prepared GNPs in vitro and in vivo, and their results showed that HEPES-prepared GNPs had better biosafety and biocompatibility than citric-prepared GNPs, 128 suggesting the biosafety and biocompatibility of nanoparticles can be improved through appropriate methods.
Conclusions
Melanoma is still difficult to cure, and the incidence rates have been rising more rapidly in recent years. The use of nanotechnology in the treatment of malignant melanoma has a bright future. It can play an important part in future melanoma therapy via various pathways. However, at present, the new agents are still in preclinical trials, with a few in clinical trials. Considering the success of so many preclinical trials, we can hope for improved therapeutic efficacy from the application of nanomedicine with therapeutic agents. However, the early applications of nanomedicine are of nanocarrier type as safety issues do not allow use of direct acting nanoparticles (PTT and PDT may act differently, though), and any wider application of nanomedicine for melanoma treatment would require an objective response rate similar to that of the best therapeutic options today (appr. 70% ORR for targeted combination of anti-PD1 1 anti-CTLA4 or BRAFi 1 MEKi). Furthermore, some problems do need to be overcome to improve the applicability of nanotechnology approaches in clinical practice. For example, problems with the biological safety and stability of nanomaterials would lead to a reduced ability to deliver drugs or an attenuated antitumor effect. Based on the structure and properties of nanoparticles, new composite nanomaterials, such as nanocarriers loaded with chemotherapeutic drugs, antibodies and nucleotide fragments, can be developed for chemotherapy, immunotherapy, and gene therapy.
